date,title,source
Oct-22-18,"VistaGen Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018",GlobeNewswire
Oct-25-18,"VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study",GlobeNewswire
Oct-29-18,VistaGen Therapeutics Reports Fiscal 2019 Second Quarter Financial Results,GlobeNewswire
Oct-29-18,"Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more",American City Business Journals
Nov-12-18,VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression,GlobeNewswire
Nov-15-18,"Consolidated Research: 2018 Summary Expectations for Tapestry, Mallinckrodt public limited company, Moxian, Applied Genetic Technologies, VistaGen Therapeutics, and Oasis Midstream Partners LP  Fundamental Analysis, Key Performance Indications",GlobeNewswire
Nov-29-18,VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101,GlobeNewswire
Dec-21-18,"Do Institutions Own VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Shares?",Simply Wall St.
Dec-27-18,VistaGen Therapeutics to Present at 11th Annual Biotech Showcase,GlobeNewswire
Jan-15-19,"VistaGen Therapeutics Appoints Pharmaceutical Industry Veteran, Ann Cunningham, to its Board of Directors",GlobeNewswire
Jan-31-19,AV-101 Stimulates the Formation of New Brain Cells in Nonclinical Studies,GlobeNewswire
